Esperion Therapeutics, Inc. (ESPR)
After hours:
| Previous close | 5.63 |
| Open | 5.69 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 2900 |
| Day's range | 5.48 - 5.69 |
| 52-week range | 3.28 - 26.77 |
| Volume | |
| Avg. volume | 1,381,053 |
| Market cap | 347.166M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.24 |
| Earnings date | 01 Aug 2022 - 05 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.80 |
- Zacks
Esperion (ESPR) Up More Than 12% YTD: What's Driving the Rally?
Esperion's (ESPR) marketed drugs are the key drivers of the stock. Sales of the drugs increase more than 100% during the first quarter. Strong sales growth is expected to continue in 2022 as well as 2023.
- GlobeNewswire
Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will participate in a fireside chat at the upcoming H.C. Wainwright Global Investment Conference on Tuesday, May 24th, 2022. Event:H.C. Wainwright Global Investment ConferenceDate:Tuesday, May 24th, 2022Format:Presentation and 1:1 MeetingsTime:7:00 am Eastern Standard TimeWebcast:Link A live audio webcast can be accessed on the investor and media
- Simply Wall St.
Esperion Therapeutics, Inc. (NASDAQ:ESPR): Are Analysts Optimistic?
Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) is possibly approaching a major achievement in its business, so we would...
